Published mark
Roivant Sciences Ltd.
NASDAQ: ROIV. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5
- SEC CIK
- 0001635088
- Website
- roivant.com Open
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 17, 2026
- Newest evidence
- Apr 24, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Eric VenkerSince Jul 29, 2025
- Chair
- Not published
- Independent
- 6 / 88 directors published
- Published claims
- 343 distinct sources
- Evidence records
- 120 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 12 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
CEO CHANGED
Eric Venker executive of Roivant Sciences Ltd., effective 2025-07-29.
EffectiveEffective Jul 29, 2025E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| President and Immunovant CEO | Eric Venker | Jul 2025 | current | Source reportedE3 |
| President and Vant Chair | Frank Torti | Jul 2025 | current | Source reportedE4 |
| Chief Accounting Officer | Jennifer Humes | Jul 2025 | current | Source reportedE7 |
| Chief Financial Officer | Richard Pulik | Jul 2025 | current | Source reportedE11 |
| Chief Technology Officer | Huafeng Xu | Not captured | unknown | Source reportedE5 |
| Chief Information Officer | Ian Rosenblum | Not captured | unknown | Source reportedE6 |
| General Counsel | Josh Chen | Not captured | unknown | Source reportedE8 |
| Chief Executive Officer & Director | Matthew Gline | Not captured | unknown | Source reportedE9 |
| President, Chief Investment Officer & Director | Mayukh Sukhatme | Not captured | unknown | Source reportedE10 |
Board of directors
Evidence8 directors published. 6 of 8 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Daniel Gold | Independent | 2020 | Compensation, chairCompensation · Chair | Source reportedE2 |
| Ilan Oren | Independent | 2014 | CompensationCompensation; Nominating and Governance · ChairNominating and Governance, chair | Source reportedE2 |
| James C. Momtazee | Independent | 2021 | Nominating and Governance | Source reportedE2 |
| Keith Manchester | Independent | 2014 | Audit | Source reportedE2 |
| Matthew Gline | Not independent | 2021 | None published | Source reportedE2 |
| Mayukh Sukhatme | Not independent | 2023 | None published | Source reportedE2 |
| Meghan FitzGerald | Independent | 2023 | AuditAudit; Nominating and GovernanceNominating and Governance | Source reportedE2 |
| Melissa Epperly | Independent | 2022 | Audit, chairAudit · Chair | Source reportedE2 |
| Mayukh Sukhatme | Independence not published | Not published | Compensation | Source reportedE12 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Melissa Epperly | Melissa Epperly, Keith Manchester, Meghan FitzGerald | Not described in the published record |
| Audit · Chair | Not published | Melissa Epperly | Not described in the published record |
| Audit; Nominating and Governance | Not published | Meghan FitzGerald | Not described in the published record |
| Compensation | Daniel Gold | Daniel Gold, Ilan Oren, Mayukh Sukhatme | Not described in the published record |
| Compensation · Chair | Not published | Daniel Gold | Not described in the published record |
| Compensation; Nominating and Governance · Chair | Not published | Ilan Oren | Not described in the published record |
| Nominating and Governance | Ilan Oren | Ilan Oren, James C. Momtazee, Meghan FitzGerald | Not described in the published record |
Committee RecordAudit: Chair Melissa Epperly; Members Melissa Epperly (Chair); Keith Manchester; Meghan FitzGerald
Committee AppointmentMelissa Epperly: chair, Audit
Committee AppointmentKeith Manchester: member, Audit
Committee AppointmentMeghan FitzGerald: member, Audit
Committee AppointmentDaniel Gold: chair, Compensation
Committee AppointmentIlan Oren: member, Compensation
Committee AppointmentMayukh Sukhatme: member, Compensation
Committee RecordNominating and Governance: Chair Ilan Oren; Members Ilan Oren (Chair); James C. Momtazee; Meghan FitzGerald
Committee AppointmentIlan Oren: chair, Nominating and Governance
Committee AppointmentJames C. Momtazee: member, Nominating and Governance
Committee AppointmentMeghan FitzGerald: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerEric Venker, President and Immunovant CEO, from Jul 29, 2025
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingROIV (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 17, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameRoivant Sciences Ltd.
Entity StatusPublic listing published
Published FactUS
Published FactHealthcare
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Eric VenkerPresident and Immunovant CEOcompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:15
- Frank TortiPresident and Vant Chaircompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:16
- Jennifer HumesChief Accounting Officercompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:19
- Richard PulikChief Financial Officercompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:23
- Huafeng XuChief Technology Officercompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:17
- Ian RosenblumChief Information Officercompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:18
- Josh ChenGeneral Counselcompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:20
- Matthew GlineChief Executive Officer & Directorcompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:21
- Mayukh SukhatmePresident, Chief Investment Officer & Director; Director (committee appointment)company:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:22, company:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:committee_record:28
- Daniel GoldDirectorcompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:7
- Ilan OrenDirectorcompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:8
- James C. MomtazeeDirectorcompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:9
- Keith ManchesterDirectorcompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:10
- Matthew GlineDirectorcompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:11
- Mayukh SukhatmeDirectorcompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:12
- Meghan FitzGeraldDirectorcompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:13
- Melissa EpperlyDirectorcompany:ab8a0d28-cfb2-41eb-8c61-cee27e51e6b5:leadership_role:14
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 12 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 17, 2026. Cited by 5 Claims.
- E2sec proxy. Published Jul 29, 2025. Retrieved Apr 29, 2026. Cited by 8 Claims.
- E3sec filing. Published Jul 29, 2025. Retrieved May 6, 2026. Cited by 1 Claim.
- E4sec filing. Published Jul 29, 2025. Retrieved May 6, 2026. Cited by 1 Claim.
- E5other. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 1 Claim.
- E6other. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 1 Claim.
- E7sec filing. Published Jul 29, 2025. Retrieved May 6, 2026. Cited by 1 Claim.
- E8other. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 1 Claim.
- E9other. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 1 Claim.
- E10other. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 1 Claim.
- E11sec filing. Published Jul 29, 2025. Retrieved May 6, 2026. Cited by 1 Claim.
- E12board_seats. board seats. Cited by 12 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 17, 2026- Eric Venker executive of Roivant Sciences Ltd., effective 2025-07-29.
- Frank Torti executive of Roivant Sciences Ltd., effective 2025-07-29.
- Jennifer Humes executive of Roivant Sciences Ltd., effective 2025-07-29.
- Richard Pulik executive of Roivant Sciences Ltd., effective 2025-07-29.
- Mayukh Sukhatme seat on Roivant Sciences Ltd., effective 2023-01-01.
- Meghan FitzGerald seat on Roivant Sciences Ltd., effective 2023-01-01.
- Audit; Nominating and Governance committee of Roivant Sciences Ltd., effective 2023-01-01.
- Meghan FitzGerald member of Audit; Nominating and Governance, effective 2023-01-01.
- Melissa Epperly seat on Roivant Sciences Ltd., effective 2022-01-01.
- Audit · Chair committee of Roivant Sciences Ltd., effective 2022-01-01.
- Melissa Epperly member of Audit · Chair, effective 2022-01-01.
- James C. Momtazee seat on Roivant Sciences Ltd., effective 2021-01-01.
- Matthew Gline seat on Roivant Sciences Ltd., effective 2021-01-01.
- James C. Momtazee member of Nominating and Governance, effective 2021-01-01.
- Daniel Gold seat on Roivant Sciences Ltd., effective 2020-01-01.
- Compensation · Chair committee of Roivant Sciences Ltd., effective 2020-01-01.
- Daniel Gold member of Compensation · Chair, effective 2020-01-01.
- Ilan Oren seat on Roivant Sciences Ltd., effective 2014-01-01.
- Keith Manchester seat on Roivant Sciences Ltd., effective 2014-01-01.
- Keith Manchester member of Audit, effective 2014-01-01.
- Compensation; Nominating and Governance · Chair committee of Roivant Sciences Ltd., effective 2014-01-01.
- Ilan Oren member of Compensation; Nominating and Governance · Chair, effective 2014-01-01.